![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
All-oral Dual Combination of Daclatasvir plus Asunaprevir Compared with Telaprevir plus Peginterferon Alfa/Ribavirin in Treatment-naive Japanese Patients Chronically infected with HCV Genotype 1b: Results from a Phase 3 Study
|
|
|
Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
Kazuaki Chayama,1 Fumitaka Suzuki,2 Yoshiyuki Suzuki,2 Joji Toyota,3 Yoshiyasu Karino,3 Yoshiiku Kawakami,1 Shigetoshi Fujiyama,4 Takayoshi Ito,5 Yoshito Itoh,6 Etsuko Tamura,7 Tomoko Ueki,7 Hiroki Ishikawa,7 Misti Linaberry,8 Eric Hughes,8 Hiromitsu Kumada2
1Hiroshima University, Hiroshima, Japan; 2Toranomon Hospital, Tokyo, Japan; 3Sapporo-Kosei General Hospital, Sapporo, Japan; 4Kumamoto Shinto General Hospital, Kumamoto, Japan; 5Showa University Koto Toyosu Hospital, Tokyo, Japan; 6Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan; 7Bristol-Myers KK, Toyko, Japan; 8Bristol Myers Squibb Research and Development, Princeton, NJ, USA
![AASLD1.gif](../images/111714/111714-7/AASLD1.gif)
![AASLD2.gif](../images/111714/111714-7/AASLD2.gif)
![AASLD3.gif](../images/111714/111714-7/AASLD3.gif)
![AASLD4.gif](../images/111714/111714-7/AASLD4.gif)
![AASLD5.gif](../images/111714/111714-7/AASLD5.gif)
![AASLD6.gif](../images/111714/111714-7/AASLD6.gif)
![AASLD7.gif](../images/111714/111714-7/AASLD7.gif)
![AASLD8.gif](../images/111714/111714-7/AASLD8.gif)
![AASLD9.gif](../images/111714/111714-7/AASLD9.gif)
![AASLD10.gif](../images/111714/111714-7/AASLD10.gif)
![AASLD11.gif](../images/111714/111714-7/AASLD11.gif)
![AASLD12.gif](../images/111714/111714-7/AASLD12.gif)
![AASLD13.gif](../images/111714/111714-7/AASLD13.gif)
![AASLD14.gif](../images/111714/111714-7/AASLD14.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|